UK Gov
As with all clinical trials, the MHRA's top priority is the safety and wellbeing of the trial participants.
Following the update published on 27 February 2026 , we are publishing, for transparency, a copy of an email sent to all MHRA staff by Chief Executive Lawrence Tallon on 11 March 2026, regarding the Pathways clinical trial.
A copy of the email is available here: MHRA staff email - 11 March 2026 (PDF, 125 KB, 2 pages)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
